|
|||||
|
|
Effective adoptive therapy of tap-deficient lymphoma using diverse high avidity alloreactive T cells |
|
| Authors: | Zoran Popmihajlov Fabio R. Santori Daniel Gebreselassie Anthony D. Sandler Stanislav Vukmanovic |
| Affiliation: | (1) Michael Heidelberger Division of Immunology, Department of Pathology and NYU Cancer Center, NYU School of Medicine, New York, NY 10016, USA;(2) Center for Cancer and Immunology Research, Children’s Research Institute, Children’s National Medical Center, 111 Michigan Avenue NW, Washington, DC 20010-2970, USA;(3) Present address: Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Rd. N.W, Washington, DC 20057, USA;(4) Present address: Department of Pathology, Skirball Institute for Molecular Medicine, NYU Cancer Center, NYU School of Medicine, 550 First Avenue, New York, NY 10016, USA;(5) Present address: Division of Immunology, Department of Medicine, Weill Medical College of Cornell University, 515 East 71st Street, S-222, New York, NY 10021, USA; |
| Abstract: | High avidity for antigen and diversity of T cell receptor (TCR) repertoire are essential for effective immunity against cancer. We have previously created a transgenic mouse strain with increased TCR avidity in a diverse T cell population. In this report, we show that strong alloreactive responses of transgenic T cells against targets with low MHC class I expression can be used for effective adoptive transfer of tumor immunity in vivo. Alloreactive transgenic T cells could be an effective therapeutic approach counteracting tumor evasion of the immune system. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |